Chemogenomics at work in the kinase gene family


Mark Namchuk, Vertex Pharmaceuticals Inc, 130 Waverly Street, Cambridge, MA 02139
Sequencing of the human genome has provided a complete membership list for the gene families that have made the best drug targets. Roughly 520 kinases have now been identified, but the pharmaceutical value of the majority of is unclear. Deciding which targets to pursue requires illumination of the target biology, but should also consider the tractability of obtaining a drug against that target. In constructing the Kinase discovery platform at Vertex, an underlying goal was to address both these questions by designing the compound collection and data gathering infrastructure to generate useful tools for new target evaluation as well as providing reasonable starting points for subsequent optimization. Key aspects of the design of the platform and examples of application tool compounds for validation studies will be discussed.

Chemogenomics: What It Is And What It Is Not
9:00 AM-11:30 AM, Wednesday, August 25, 2004 Pennsylvania Convention Center -- 201C, Oral

Biotechnology Secretariat

The 228th ACS National Meeting, in Philadelphia, PA, August 22-26, 2004